Combination of midazolam and a cyclooxygenase-2 inhibitor inhibits lipopolysaccharide-induced interleukin-6 production in human peripheral blood mononuclear cells

Takuya Miyawaki, Atsushi Kohjitani, Shigeru Maeda, Hitoshi Higuchi, Yukiko Arai, Yumiko Tomoyasu, Masahiko Shimada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Context: Interleukin-6 (IL-6) plays an important role in immune and inflammatory responses. Midazolam has been reported to modulate IL-6 response. Cyclooxygenase (COX) inhibitors, which are used together with midazolam in some patients undergoing surgery, also modulate it. We hypothesized that their combination results in eliciting the synergistical effect on the IL-6 response. Objective: The aim of the present study was to evaluate the effect of the combination of midazolam and a COX inhibitor on IL-6 production. Materials and methods: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and incubated with lipopolysaccharide (LPS), midazolam, and/or COX inhibitors, including indomethacin, SC-560, a COX-1 selective inhibitor, and NS-398, a COX-2 selective inhibitor. The supernatant concentrations of IL-6 and prostaglandins (PGs), including PGE2, PGF2α, PGD2, and 15-deoxy-Δ 12,14-prostaglandin J2 (15dPGJ2) were measured. Results: Midazolam had no effect on IL-6 production in the cells incubated for 12h, and any COX inhibitors also had no effect. However, the combination of midazolam and NS-398 significantly inhibited it. Midazolam raised the concentration of 15dPGJ2 in the supernatant of the cells, but not the concentration of other PGs. Disscussion and conclusion: The results in the present study demonstrated that the combination of midazolam and a COX-2 inhibitor inhibited LPS-induced IL-6 production in human PBMCs even if each drug separately did not have any effect on it. The finding suggests that their combination is effective against excessive IL-6 production such as severe inflammatory response and that the effect of midazolam on IL-6 production is possibly elicited via 15dPGJ2.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalImmunopharmacology and Immunotoxicology
Volume34
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Cyclooxygenase 2 Inhibitors
Midazolam
Lipopolysaccharides
Interleukin-6
Blood Cells
Blood
Cyclooxygenase Inhibitors
Prostaglandins
Prostaglandin D2
Cyclooxygenase 1
Dinoprost
Cyclooxygenase 2
Dinoprostone
Indomethacin
Surgery
Healthy Volunteers

Keywords

  • Anesthetics
  • COX inhibitor
  • Interleukin-6
  • Midazolam
  • Prostaglandin

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology

Cite this

Combination of midazolam and a cyclooxygenase-2 inhibitor inhibits lipopolysaccharide-induced interleukin-6 production in human peripheral blood mononuclear cells. / Miyawaki, Takuya; Kohjitani, Atsushi; Maeda, Shigeru; Higuchi, Hitoshi; Arai, Yukiko; Tomoyasu, Yumiko; Shimada, Masahiko.

In: Immunopharmacology and Immunotoxicology, Vol. 34, No. 1, 02.2012, p. 79-83.

Research output: Contribution to journalArticle

@article{262ff1e7120b4d8c8006133d2ce38fb4,
title = "Combination of midazolam and a cyclooxygenase-2 inhibitor inhibits lipopolysaccharide-induced interleukin-6 production in human peripheral blood mononuclear cells",
abstract = "Context: Interleukin-6 (IL-6) plays an important role in immune and inflammatory responses. Midazolam has been reported to modulate IL-6 response. Cyclooxygenase (COX) inhibitors, which are used together with midazolam in some patients undergoing surgery, also modulate it. We hypothesized that their combination results in eliciting the synergistical effect on the IL-6 response. Objective: The aim of the present study was to evaluate the effect of the combination of midazolam and a COX inhibitor on IL-6 production. Materials and methods: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and incubated with lipopolysaccharide (LPS), midazolam, and/or COX inhibitors, including indomethacin, SC-560, a COX-1 selective inhibitor, and NS-398, a COX-2 selective inhibitor. The supernatant concentrations of IL-6 and prostaglandins (PGs), including PGE2, PGF2α, PGD2, and 15-deoxy-Δ 12,14-prostaglandin J2 (15dPGJ2) were measured. Results: Midazolam had no effect on IL-6 production in the cells incubated for 12h, and any COX inhibitors also had no effect. However, the combination of midazolam and NS-398 significantly inhibited it. Midazolam raised the concentration of 15dPGJ2 in the supernatant of the cells, but not the concentration of other PGs. Disscussion and conclusion: The results in the present study demonstrated that the combination of midazolam and a COX-2 inhibitor inhibited LPS-induced IL-6 production in human PBMCs even if each drug separately did not have any effect on it. The finding suggests that their combination is effective against excessive IL-6 production such as severe inflammatory response and that the effect of midazolam on IL-6 production is possibly elicited via 15dPGJ2.",
keywords = "Anesthetics, COX inhibitor, Interleukin-6, Midazolam, Prostaglandin",
author = "Takuya Miyawaki and Atsushi Kohjitani and Shigeru Maeda and Hitoshi Higuchi and Yukiko Arai and Yumiko Tomoyasu and Masahiko Shimada",
year = "2012",
month = "2",
doi = "10.3109/08923973.2011.577783",
language = "English",
volume = "34",
pages = "79--83",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Combination of midazolam and a cyclooxygenase-2 inhibitor inhibits lipopolysaccharide-induced interleukin-6 production in human peripheral blood mononuclear cells

AU - Miyawaki, Takuya

AU - Kohjitani, Atsushi

AU - Maeda, Shigeru

AU - Higuchi, Hitoshi

AU - Arai, Yukiko

AU - Tomoyasu, Yumiko

AU - Shimada, Masahiko

PY - 2012/2

Y1 - 2012/2

N2 - Context: Interleukin-6 (IL-6) plays an important role in immune and inflammatory responses. Midazolam has been reported to modulate IL-6 response. Cyclooxygenase (COX) inhibitors, which are used together with midazolam in some patients undergoing surgery, also modulate it. We hypothesized that their combination results in eliciting the synergistical effect on the IL-6 response. Objective: The aim of the present study was to evaluate the effect of the combination of midazolam and a COX inhibitor on IL-6 production. Materials and methods: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and incubated with lipopolysaccharide (LPS), midazolam, and/or COX inhibitors, including indomethacin, SC-560, a COX-1 selective inhibitor, and NS-398, a COX-2 selective inhibitor. The supernatant concentrations of IL-6 and prostaglandins (PGs), including PGE2, PGF2α, PGD2, and 15-deoxy-Δ 12,14-prostaglandin J2 (15dPGJ2) were measured. Results: Midazolam had no effect on IL-6 production in the cells incubated for 12h, and any COX inhibitors also had no effect. However, the combination of midazolam and NS-398 significantly inhibited it. Midazolam raised the concentration of 15dPGJ2 in the supernatant of the cells, but not the concentration of other PGs. Disscussion and conclusion: The results in the present study demonstrated that the combination of midazolam and a COX-2 inhibitor inhibited LPS-induced IL-6 production in human PBMCs even if each drug separately did not have any effect on it. The finding suggests that their combination is effective against excessive IL-6 production such as severe inflammatory response and that the effect of midazolam on IL-6 production is possibly elicited via 15dPGJ2.

AB - Context: Interleukin-6 (IL-6) plays an important role in immune and inflammatory responses. Midazolam has been reported to modulate IL-6 response. Cyclooxygenase (COX) inhibitors, which are used together with midazolam in some patients undergoing surgery, also modulate it. We hypothesized that their combination results in eliciting the synergistical effect on the IL-6 response. Objective: The aim of the present study was to evaluate the effect of the combination of midazolam and a COX inhibitor on IL-6 production. Materials and methods: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and incubated with lipopolysaccharide (LPS), midazolam, and/or COX inhibitors, including indomethacin, SC-560, a COX-1 selective inhibitor, and NS-398, a COX-2 selective inhibitor. The supernatant concentrations of IL-6 and prostaglandins (PGs), including PGE2, PGF2α, PGD2, and 15-deoxy-Δ 12,14-prostaglandin J2 (15dPGJ2) were measured. Results: Midazolam had no effect on IL-6 production in the cells incubated for 12h, and any COX inhibitors also had no effect. However, the combination of midazolam and NS-398 significantly inhibited it. Midazolam raised the concentration of 15dPGJ2 in the supernatant of the cells, but not the concentration of other PGs. Disscussion and conclusion: The results in the present study demonstrated that the combination of midazolam and a COX-2 inhibitor inhibited LPS-induced IL-6 production in human PBMCs even if each drug separately did not have any effect on it. The finding suggests that their combination is effective against excessive IL-6 production such as severe inflammatory response and that the effect of midazolam on IL-6 production is possibly elicited via 15dPGJ2.

KW - Anesthetics

KW - COX inhibitor

KW - Interleukin-6

KW - Midazolam

KW - Prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=84055184519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055184519&partnerID=8YFLogxK

U2 - 10.3109/08923973.2011.577783

DO - 10.3109/08923973.2011.577783

M3 - Article

C2 - 21854184

AN - SCOPUS:84055184519

VL - 34

SP - 79

EP - 83

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 1

ER -